Literature DB >> 16154793

Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP).

Spiridon Papapetropoulos1, Carlos Singer, Donald McCorquodale, Jocely Gonzalez, Deborah C Mash.   

Abstract

The aim of this study was to investigate the causes and seasonality of death and co-morbid conditions among progressive supranuclear palsy (PSP) patients. 22 consecutive clinicopathologically confirmed PSP patients were compared with 22 gender and age-matched Parkinson's disease (PD) patients and 26 non-neurological controls. All subjects consented during life to donate their brains to the University of Miami Brain Endowment Bank. Respiratory-related deaths were significantly more frequent in PSP when compared to PD patients. Recurrent respiratory infections were also very frequent in PSP patients and were commonly associated with respiratory-related deaths. Deaths that occurred during winter and spring months accounted for about 70% of deaths among PSP patients. The most common co-morbid condition in PSP was hypertension, present in 50% of cases.

Entities:  

Mesh:

Year:  2005        PMID: 16154793     DOI: 10.1016/j.parkreldis.2005.06.003

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Time trends and seasonal patterns of health-related quality of life among U.S. adults.

Authors:  Haomiao Jia; Erica I Lubetkin
Journal:  Public Health Rep       Date:  2009 Sep-Oct       Impact factor: 2.792

2.  Idiopathic adult onset action dystonia of the lower limbs: case reports.

Authors:  Jose Fidel Baizabal Carvallo; Marie Vidailhet
Journal:  J Neurol       Date:  2011-03-22       Impact factor: 4.849

3.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  [Progressive supranuclear palsy: living environment of the patients in Germany].

Authors:  M Hensler; S Paul; C Abright; S Lorenzl
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

5.  Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Authors:  Tien Dam; Adam L Boxer; Lawrence I Golbe; Günter U Höglinger; Huw R Morris; Irene Litvan; Anthony E Lang; Jean-Christophe Corvol; Ikuko Aiba; Michael Grundman; Lili Yang; Beth Tidemann-Miller; Joseph Kupferman; Kristine Harper; Kubra Kamisoglu; Michael J Wald; Danielle L Graham; Liz Gedney; John O'Gorman; Samantha Budd Haeberlein
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

6.  A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.

Authors:  Boyd C P Ghosh; Roger H S Carpenter; James B Rowe
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

7.  Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy.

Authors:  Margherita Canesi; Rosaria Giordano; Lorenza Lazzari; Maurizio Isalberti; Ioannis Ugo Isaias; Riccardo Benti; Paolo Rampini; Giorgio Marotta; Aurora Colombo; Emanuele Cereda; Mariangela Dipaola; Tiziana Montemurro; Mariele Viganò; Silvia Budelli; Elisa Montelatici; Cristiana Lavazza; Agostino Cortelezzi; Gianni Pezzoli
Journal:  J Transl Med       Date:  2016-05-10       Impact factor: 5.531

Review 8.  Epidemiology of atypical parkinsonian syndromes.

Authors:  Raymond Y Lo
Journal:  Tzu Chi Med J       Date:  2021-01-19

Review 9.  Disease modification in Parkinsonism: obstacles and ways forward.

Authors:  M Höllerhage; M Klietz; G U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-13       Impact factor: 3.850

10.  Role of Hypertension in Aggravating Abeta Neuropathology of AD Type and Tau-Mediated Motor Impairment.

Authors:  C Díaz-Ruiz; J Wang; H Ksiezak-Reding; L Ho; X Qian; N Humala; S Thomas; P Martínez-Martín; G M Pasinetti
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.